The US is the bigger Biosimilars market: $15.5 Bn against $671 Mn in 2023, about 23 times as large.
India grows faster: 27.9% a year, against 22.9%. The gap still grows from $14.8 Bn to $114 Bn by 2033.
Clinical research: 351 active trials in the US, 4 in India.
| Measure |  US |  India |
|---|---|---|
| Market size, 2023 | $15.5 Bn | $671 Mn |
| Market size, 2033 projected | $121.8 Bn | $7.9 Bn |
| Growth a year (CAGR) | 22.9% | 27.9% |
| Money added, 2023–2033 | $106.3 Bn | $7.2 Bn |
| Share of the world market | 42% | 1.8% |
| Size rank of 24 countries | #1 | #12 |
| Market per person, 2023 | $45 | $0.46 |
| Active clinical trials | 351 | 4 |
| Full report | US report | India report |
Year by year, 2023 to 2033
US India · values between 2023 and 2033 are projected from the 2023 size and the CAGR.
Quick answers
Which is bigger in Biosimilars, US or India?
The US is the bigger Biosimilars market: $15.5 Bn against $671 Mn in 2023, about 23 times as large.
Which grows faster in Biosimilars, US or India?
India grows faster: 27.9% a year, against 22.9%. The gap still grows from $14.8 Bn to $114 Bn by 2033.
More Biosimilars comparisons
Sources: market size and growth: Acuitas Health Analytics research (2023 base year, forecasts to 2033). Trials: ClinicalTrials.gov (fetched 10 Nov 2026); found by search words, so counts are a guide. Population: World Bank.